靶向肿瘤多药耐药基因mdr1的siRNA的构建与鉴定

mdr 1基因及其表达产物P-gp是引起肿瘤细胞多药耐药(MDR)的主要原因,抑制mdr 1基因的表达可用于逆转MDR.RNAi可用于特异抑制靶基因的表达,本研究的目的是构建获得可特异有效靶向mdr 1基因的siRNA元件.应用siRNA设计软件与mRNA结构分析软件设计构建了3个分别靶向mdr 1基因mRNA环结构和茎结构的siRNA元件,同时构建了携带mdr1基因序列的luc报告质粒,通过siRNA表达质粒与携带靶序列的报告质粒的共转染抑制实验检测不同siRNA的抑制效率,结果显示靶向环结构siMDR1B具有较好的抑制效率和特异性.进一步将siMDR1B表达载体与mdr1基因表达载体共转染细胞,应用免疫流式细胞术检测显示,相比对照细胞,siMDR1B可显著抑制其转染后mdr1基因产物P-gp蛋白的表达活性.同时采用CCK-8细胞活性检测试剂评价了siMDR1B对细胞活性的影响,结果显示siMDR1B不会影响细胞活性,具有良好的特异性.本研究获得的可有效靶向mdr 1基因的siRNA元件可为进一步开展逆转MDR研究提供重要基础.     

Intracellular siRNA delivery with novel spermine based surfactants

The design and development of safe and effective multifunctional siRNA delivery systems are critical for clinical application of RNAi therapeutics. Here we evaluated eight new spermine-based surfactant multifunctional carriers for siRNA delivery. These carriers complexed with siRNA forming stable compact nanoparticles with sizes around 100 nm. The multifunctional carriers mediated higher intracellular siRNA transfection than Lipofectamine-2000. The siRNA nanoparticles of the multifunctional carriers exhibited low cytotoxicity as shown by MTT assay. Three of the eight multifunctional carriers showed higher silencing efficiency than Lipofectamine-2000 in both U87-Luc cells and CHO-GFP cells. SKAHCO showed the highest siRNA delivery efficiency among the carriers. It resulted in 84.6±5.5% silencing of luciferase activity in U87-Luc cells, much higher than that (62.8± 3.4%) from Lipofectamine-2000. In conclusion, the spermine based multifunctional carriers are promising for highly efficient intracellular siRNA delivery.     

RNAi技术研究进展

RNAi是由双链RNA引起的基因沉默现象，它通过降解具有同源序列的mRNA起作用，特殊设计的siRNA能使目的基因发生特异性沉默．目前，获得siRNA已经非常方便，导入方式最常用的是微注射．RNAi技术有编码区RNAi和启动子区RNAi两大类，均可以产生类似基因敲除的功能。在家蚕功能基因的研究中已经使用了这种方法．随着RNAi技术的不断进步，RNAi可广泛地应用到功能基因组学，药物靶点筛选，疾病治疗等方面．     

RNAi-mediated gene silencing in non-human primates

The opportunity to harness the RNA interference (RNAi) pathway to silence disease-causing genes holds great promise for the development of therapeutics directed against targets that are otherwise not addressable with current medicines. Although there are numerous examples of in vivo silencing of target genes after local delivery of small interfering RNAs (siRNAs), there remain only a few reports of RNAi-mediated silencing in response to systemic delivery of siRNA, and there are no reports of systemic efficacy in non-rodent species. Here we show that siRNAs, when delivered systemically in a liposomal formulation, can silence the disease target apolipoprotein B (ApoB) in non-human primates. APOB-specific siRNAs were encapsulated in stable nucleic acid lipid particles (SNALP) and administered by intravenous injection to cynomolgus monkeys at doses of 1 or 2.5 mg kg(-1). A single siRNA injection resulted in dose-dependent silencing of APOB messenger RNA expression in the liver 48 h after administration, with maximal silencing of >90%. This silencing effect occurred as a result of APOB mRNA cleavage at precisely the site predicted for the RNAi mechanism. Significant reductions in ApoB protein, serum cholesterol and low-density lipoprotein levels were observed as early as 24 h after treatment and lasted for 11 days at the highest siRNA dose, thus demonstrating an immediate, potent and lasting biological effect of siRNA treatment. Our findings show clinically relevant RNAi-mediated gene silencing in non-human primates, supporting RNAi therapeutics as a potential new class of drugs.     

RNA干涉及其在肿瘤研究中的应用

RNAi是双链RNA介导的转录后基因沉默的过程，是一种高效的高特异性抑制基因表达的新途径。通过双链小干涉RNA(siRNA)与一系列蛋白质结合形成siRNA诱导的沉默复合体(RISC)并活化，然后，RISC对靶基因进行识别、降解。与反义方法相比，siRNA具有更好的抑制效果。RNAi的应用将为癌症的基因治疗提供新的方法。     

纳米载药体系在肿瘤耐药治疗中的应用研究进展

肿瘤是目前引起人类死亡的棘手疾病之一,虽然通过各种现代化治疗手段使肿瘤患者的预后得到了一定程度的改善,但多药耐药依然是导致肿瘤治疗效果不佳的主要难题。纳米材料是近年来的研究热点之一,具有EPR（enhanced permeability and retention）效应、可控修饰、靶向性等众多优点,在突破肿瘤耐药方面得到了愈来愈多的关注。纳米载药体系在肿瘤治疗中发挥着极其重要的作用,可以成为逆转肿瘤耐药的新方式。从肿瘤多药耐药机制、纳米技术在肿瘤耐药中的应用等方面进行综述。指出今后可在以下方面展开深入研究：1）结合肿瘤耐药机制研究,合理控制药物浓度,克服耐药;2）深入探索纳米载药体系的生物安全问题,优化纳米载药系统,使其避免或降低可能出现的毒副反应,为逆转肿瘤耐药提供更全面的理论依据;3）结合免疫学、光动力学、声动力学等多种方法,提高纳米载药体系逆转肿瘤耐药的效率。     

肿瘤细胞多药耐药逆转研究

肿瘤细胞多药耐药(MDR)是导致肿瘤化疗失败的原因之一,如何克服MDR,提高化疗疗效已成为国内外研究的热点.文章对肿瘤MDR逆转进行了研究.     

siRNA分子设计研究进展

为了设计高效的siRNA（Short interfering Ribonucleic Acid）分子、最大限度地减少siRNA分子的脱靶效应（off-target effects），siRNA分子设计已经成为热门研究领域。siRNA分子设计主要是基于序列和能量特征，以及靶标的二级结构特征，基于这些特征设计的siRNA分子已经有了较高的抑制基因表达的效率。RNAi（RNA interference）在
基因发现以及疾病治疗领域已有非常广泛的应用，就siRNA分子设计近年的研究进展作一综述，为今后siRNA研究提供参考。     

在Hep G2细胞中利用siRNA沉默GFP基因的实验探讨

目的:通过探讨小分子双链RNA(siRNA)通过RNA干扰(RNAi)机制沉默肝癌细胞株Hep G2荧光素报告基因GFP的各项生物学指标,为进一步实验和临床研究提供依据.方法:通过体外实验,对siRNA和siRNA脂质体的稳定性和细胞毒性进行评估;通过荧光标记技术,研究不同时间siRNA脂质体的转染效率;通过荧光显微镜下观察转染细胞和RT-PCR检测靶基因mRNA表达,确定不同种类、形式、剂量的siRNA对靶基因的沉默效能.结果:在空白培养液中,siRNA和siRNA脂质体可稳定至4h,在5%血清中2～4h后明显降解;100nM的siRNA和siRNA脂质体无明显细胞毒性;siRNA脂质体转染细胞株的效率随时间不同而不同,4h可达90%;非特异性siRNA/脂质体无沉默靶基因表达作用,特异性siRNA/脂质体对靶基因的沉默作用在一定范围内随剂量升高(20nM、50nM、100nM)而升高.结论:siRNA的稳定性可满足实验需要,且无明显细胞毒性,特异性siRNA转染肝癌细胞株能有效抑制靶基因表达,用脂质体转染可提高转染效率.siRNA通过RNAi机制沉默靶基因表达,为肿瘤的治疗和基础研究提供了新的工具和思路.     

A large-scale RNAi screen in human cells identifies new components of the p53 pathway

RNA interference (RNAi) is a powerful new tool with which to perform loss-of-function genetic screens in lower organisms and can greatly facilitate the identification of components of cellular signalling pathways. In mammalian cells, such screens have been hampered by a lack of suitable tools that can be used on a large scale. We and others have recently developed expression vectors to direct the synthesis of short hairpin RNAs (shRNAs) that act as short interfering RNA (siRNA)-like molecules to stably suppress gene expression. Here we report the construction of a set of retroviral vectors encoding 23,742 distinct shRNAs, which target 7,914 different human genes for suppression. We use this RNAi library in human cells to identify one known and five new modulators of p53-dependent proliferation arrest. Suppression of these genes confers resistance to both p53-dependent and p19ARF-dependent proliferation arrest, and abolishes a DNA-damage-induced G1 cell-cycle arrest. Furthermore, we describe siRNA bar-code screens to rapidly identify individual siRNA vectors associated with a specific phenotype. These new tools will greatly facilitate large-scale loss-of-function genetic screens in mammalian cells.     

慢病毒介导的HPV16-E7基因RNAi细胞模型的建立

 建立HPV16-E7基因的RNAi细胞模型,可为进一步研究HPV16-E7蛋白作用及致癌机制提供物质前提。选择HPV16-E7基因特异的siRNA片段,构建慢病毒siRNA重组表达载体,经293FT病毒包装细胞转染产生重组病毒,并以此感染HPV16阳性SiHa宫颈癌细胞、抗菌素筛选和分子生物学鉴定,建立了稳定表达HPV16-E7-siRNA的RNAi细胞模型。该细胞模型,对目标基因（E7）表达的抑制效率,也以蛋白免疫印迹和RT-PCR确证。由此得出,利用慢病毒载体和HPV16-E7基因特异的siRNA片段,可以建立一种稳定、有效和可行的RNAi细胞模型,为进一步研究E7蛋白的作用及致癌机制奠定了重要的物质基础。     

RNAi作用机制及其应用研究进展

在Dicer酶作用下,dsRNA形成siRNA,组装成具有活性的蛋白质复合物RISC,触发染色质固缩,DNA甲基化、基因沉默和干扰蛋白质合成等。RNAi基因沉默高效、特异和简捷等优点,为细胞内基因表达研究提供了新思路、新方法,为临床治疗遗传性基因扩增型疾病提供极具潜力的全新策略。文章就RNAi机制及其应用研究做一综述。     

Animal virus replication and RNAi-mediated antiviral silencing in Caenorhabditis elegans

The worm Caenorhabditis elegans is a model system for studying many aspects of biology, including host responses to bacterial pathogens, but it is not known to support replication of any virus. Plants and insects encode multiple Dicer enzymes that recognize distinct precursors of small RNAs and may act cooperatively. However, it is not known whether the single Dicer of worms and mammals is able to initiate the small RNA-guided RNA interference (RNAi) antiviral immunity as occurs in plants and insects. Here we show complete replication of the Flock house virus (FHV) bipartite, plus-strand RNA genome in C. elegans. We show that FHV replication in C. elegans triggers potent antiviral silencing that requires RDE-1, an Argonaute protein essential for RNAi mediated by small interfering RNAs (siRNAs) but not by microRNAs. This immunity system is capable of rapid virus clearance in the absence of FHV B2 protein, which acts as a broad-spectrum RNAi inhibitor upstream of rde-1 by targeting the siRNA precursor. This work establishes a C. elegans model for genetic studies of animal virus-host interactions and indicates that mammals might use a siRNA pathway as an antiviral response.     

MDR1-targeted siRNA delivery with cationic dendritic conjugated polymers

A cationic dendritic polyfluorene (PFP) is examined as a siRNA delivery vector. This material was designed to facilitate the nucleic acid binding, encapsulation and efficient cellular uptake. PFP can effectively protect siRNA against nuclease degradation, which is necessary for gene carriers. PFP can be used for multidrug resistance gene-targeted siRNA delivery in doxorubicin (Dox)-resistant human breast cancer cells (MCF7) cells. As a siRNA transfection agent, PFP can efficiently achieve the reversal of drug resistance and enhance the drug sensitivity. These new features and capabilities represent a major step toward conjugated polymers that can function for therapeutic application.     

实时无标记肿瘤细胞迁移筛选技术体系的建立

肿瘤转移是导致肿瘤患者死亡的最主要原因。细胞迁移在多步骤、多阶段的肿瘤转移过程中发挥着重要的作用。尽管有许多迁移相关分子的研究,但细胞迁移的分子机制仍不清楚。研究将xCELLigence细胞分析系统和RNA干扰技术结合,初步建立了实时无标记的肿瘤细胞迁移筛选技术体系。该技术体系的建立将为大规模的肿瘤细胞迁移筛选工作奠定基础,还将有助于发现肿瘤细胞迁移信号通路中新的调控分子,揭示肿瘤转移的分子机制。     

Recent advances of morphology adaptive nanomaterials for anti-cancer drug delivery

The morphology of nanomaterials combines the characteristics of their size, shape and spatial structure. Owing to the improved spatiotemporal control of the nanocarriers for anti-cancer drug delivery, the morphology adaptive nanomaterials have received tremendous attention in the field of nanomedicine, while they are able to respond through chemical or physical change. In this review, we summarize the recent advancements of morphology adaptive nanomaterials and their application in anti-cancer drug delivery system, wherein the size, shape and spatial structure of nanocarriers can be changed to adapt the complex living system, thus overcoming the pathological barriers in drug delivery. The overview of the recent examples shows that each step of delivery process can be improved by the morphology adaption, which represents the great potential for clinic translation of morphology adaptive nanomaterials.     

Hela细胞中突变PSF蛋白对细胞增殖迁移及可变剪接的影响

PSF作为真核细胞中的抑癌蛋白,在Hela细胞发生基因突变导致其蛋白功能改变.为了阐明突变体PSF蛋白在肿瘤细胞的作用,本文分别采用siRNA干扰、细胞生长曲线、细胞划痕等实验检测muPSF对Hela细胞增殖及迁移的影响,半定量PCR实验分析PSF调控的下游靶基因的可变剪切情况.研究结果显示,当通过siRNA干扰muPSF的表达后Hela细胞的增殖迁移能力下降,高表达突变体PSF可增强Hela细胞的增殖与迁移,半定量PCR实验分析PSF下游调控基因显示muPSF可以改变增殖和迁移相关基因的可变剪接形式.因此,我们的实验证明,Hela细胞中muPSF通过调控下游靶基因的可变剪切影响Hela细胞的增殖和迁移能力.